Alfasigma S.p.a.
Clinical trials sponsored by Alfasigma S.p.a., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could ease juvenile arthritis in kids Results expected Jun 2027 (estimated)
-
Ulcerative colitis drug filgotinib tested for Long-Term safety in over 1,100 patients
Disease control CompletedThis study looks at the long-term safety of filgotinib, a drug for ulcerative colitis, in over 1,100 adults who already took part in a filgotinib trial. The main goal is to track side effects and lab test changes over time. Participants must have completed a prior filgotinib stud…
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can filgotinib safely control rheumatoid arthritis over years? a large trial seeks answers.
Disease control CompletedThis trial is testing the long-term safety and tolerability of the drug filgotinib in people with rheumatoid arthritis who have already completed an earlier filgotinib study. Researchers are monitoring side effects, lab abnormalities, and vital signs over an extended period. The …
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Real-world filgotinib study tracks arthritis control over 2 years
Disease control CompletedThis study followed 155 French adults with moderate-to-severe rheumatoid arthritis who were prescribed filgotinib (Jyseleca) for the first time. Over two years, researchers measured how many patients stayed on the drug and how well it controlled their disease activity. The goal w…
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC